Aspirin has selective benefit in colorectal cancer | Science News

SUPPORT SCIENCE NEWS

Help us keep you informed.

Real Science. Real News.


News

Aspirin has selective benefit in colorectal cancer

Patients with gene mutation appear to gain advantage from drug

By
5:51pm, October 24, 2012

The mystery of why aspirin helps some colorectal cancer patients but not others may be partially solved. A new study finds that the drug seems to extend survival in patients whose tumors harbor a specific genetic mutation, while patients lacking the mutation get no survival advantage from regularly taking the pills.

The study, in the Oct. 25 New England Journal of Medicine, may lead to standardized testing of colorectal cancer patients for the mutation, in a gene called PIK3CA, to see who would benefit from aspirin use.

“We may be witnessing a game changer,” says Boris Pasche, an oncologist at the University of Alabama at Birmingham who wasn’t part of the study team. “I wouldn’t be surprised to see labs beginning to test for this mutation quickly.”

The study will need to be validated in a randomized clinical trial before a PIK3CA test becomes part of treatment guidelines, Pasche says. Roughly 15

This article is only available to Science News subscribers. Already a subscriber? Log in now. Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content